Today's headline has an immediate bedside use: before concluding that a JAK inhibitor has failed in a patient with obesity, record the BMI and factor it into the judgement. A blunted response at high BMI is expected, not necessarily a reason to switch mechanism — and it is a concrete, shared reason to bring weight management into the treatment conversation rather than leaving it to a separate clinic the patient may never reach.
- Record BMI as part of assessing response to a JAK inhibitor
- A smaller response at high BMI may be expected rather than true drug failure
- Use it as a shared, specific reason to address weight, not a generic instruction
- Do not switch mechanism on a borderline response without accounting for BMI
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free